Abstract
Survival probability in children, adolescents, and young adults with chronic myeloid leukemia (CML) has dramatically improved during recent years. Tyrosine kinase inhibitors (TKI), targeted drugs developed for patients with CML, were introduced in 2001 in England. We here quantify the trends in the "cure" proportion according to the year of diagnosis. We included all children, adolescents, and young patients with CML (0 to 24 years) diagnosed in England during 1980 to 2005. We fitted mixture cure models to estimate the "cure" proportion and the median survival time among the "uncured" patients according to the year of diagnosis, adjusted for age at diagnosis. The "cure" proportion increased dramatically between 1980 and 2005, from under 10% to over 80%, while conversely, the median survival time of "uncured" patients decreased slightly between 1980 and 1999, with the trend from 2000 being uncertain. The striking improvement of the "cure" fraction in young patients with CML since the early 1980s is concomitant with improvement of treatment, especially the allogeneic hematopoietic stem-cell transplant and, later, the introduction of TKI. The trends over the last years (2000-2005) remain, however, uncertain and would benefit from ...Continue Reading
References
Jul 15, 1998·International Journal of Cancer. Journal International Du Cancer·A VerdecchiaF Berrino
Mar 10, 1999·Statistics in Medicine·R De AngelisA Verdecchia
Jan 10, 2002·Statistics in Medicine·Richard Sposto
Jan 31, 1953·Lancet·A HADDOW, G M TIMMIS
Jul 3, 2004·Blood·Martin A ChampagneUNKNOWN Children's Oncology Group phase 1 study
Feb 12, 2008·European Journal of Epidemiology·Theodora Bejan-AngoulvantLaurent Remontet
Jul 3, 2008·British Journal of Cancer·A ShahM P Coleman
Mar 24, 2009·The Lancet Oncology·Bernard RachetMichel P Coleman
Nov 6, 2009·Klinische Pädiatrie·M SuttorpT Klingebiel
Jan 14, 2011·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Meinolf SuttorpKirk R Schultz
Jun 15, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Frédéric MillotFrançois Guilhot
Jun 24, 2011·BMC Medical Research Methodology·Therese M L AnderssonPaul C Lambert
Jun 8, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Megan OthusJohn J Crowley
Feb 14, 2013·Haematologica·Gemma GattaUNKNOWN EUROCARE Working Group
May 2, 2013·Haematologica·Christian Michel Zwaan, Richard Sposto
Jun 22, 2013·British Journal of Haematology·Anjali ShahPaul C Lambert
Sep 7, 2013·Computer Methods and Programs in Biomedicine·Edson Z MartinezJosé S Santos
Sep 18, 2013·Cancer Epidemiology·X Q YuP W Dickman
Jul 1, 2014·British Journal of Haematology·Josu de la FuenteUNKNOWN International BFM Group (iBFM) Study Group Chronic Myeloid Leukaemia Committee
Mar 31, 2015·British Journal of Haematology·Niklas GunnarssonAnders Själander
Apr 22, 2015·British Journal of Haematology·Fiorina GionaRobin Foà
Oct 30, 2015·Blood·Nobuko HijiyaMeinolf Suttorp
May 31, 2016·The Lancet Oncology·Annalisa TramaUNKNOWN EUROCARE-5 Working Group
Jun 22, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hannah BowerTherese M-L Andersson
Nov 15, 2016·Best Practice & Research. Clinical Haematology·François-Xavier Mahon
Sep 6, 2017·Journal of Theoretical Biology·Daniel KochAlexander Gebharter
Citations
Dec 7, 2018·American Journal of Respiratory and Critical Care Medicine·Chloe I BloomPaul Cullinan
Feb 13, 2020·Medicine·Mengyue DengJie Yu
Oct 10, 2020·Pediatric Blood & Cancer·Adalet Meral GünesMeinolf Suttorp
Jan 12, 2021·Cancer Science·Kayo NakataUNKNOWN Osaka Cancer Association for Children, Adolescents, Young Adults
Nov 22, 2020·Cancers·Daniël J van der MeerOlga Husson
Jul 23, 2021·Paediatric Drugs·Athanasios Tragiannidis, Andreas H Groll